Next Article in Journal
Contribution of the Degeneration of the Neuro-Axonal Unit to the Pathogenesis of Multiple Sclerosis
Next Article in Special Issue
Phenotypic Discordance in Siblings with Identical Compound Heterozygous PARK2 Mutations
Previous Article in Journal
Neuropsychiatric Burden in Huntington’s Disease
Article Menu

Export Article

Open AccessReview
Brain Sci. 2017, 7(6), 68; doi:10.3390/brainsci7060068

Brain Magnetic Resonance Imaging (MRI) as a Potential Biomarker for Parkinson’s Disease (PD)

Neurology Department, University of Minnesota, MMC 295, 420 Delaware St SE, Minneapolis, MN 55455, USA
Academic Editors: Steven Frucht and Pichet Termsarasab
Received: 28 April 2017 / Revised: 9 June 2017 / Accepted: 13 June 2017 / Published: 16 June 2017
(This article belongs to the Special Issue Pathophysiology and Genetics of Movement Disorders)
View Full-Text   |   Download PDF [232 KB, uploaded 16 June 2017]

Abstract

Magnetic resonance imaging (MRI) has the potential to serve as a biomarker for Parkinson’s disease (PD). However, the type or types of biomarker it could provide remain to be determined. At this time there is not sufficient sensitivity or specificity for MRI to serve as an early diagnostic biomarker, i.e., it is unproven in its ability to determine if a single individual is normal, has mild PD, or has some other forms of degenerative parkinsonism. However there is accumulating evidence that MRI may be useful in staging and monitoring disease progression (staging biomarker), and also possibly as a means to monitor pathophysiological aspects of disease and associated response to treatments, i.e., theranostic marker. As there are increasing numbers of manuscripts that are dedicated to diffusion- and neuromelanin-based imaging methods, this review will focus on these topics cursorily and will delve into pharmacodynamic imaging as a means to get at theranostic aspects of PD. View Full-Text
Keywords: diffusion tensor imaging (DTI); fractional anisotropy (FA); functional MRI (fMRI); magnetic resonance imaging (MRI); magnetic resonance spectroscopy (MRS); neuromelanin; pharmacodynamic MRI (phMRI); resting state-fMRI (rs-fMRI); theranostics; voxel-based morphometry (VBM) diffusion tensor imaging (DTI); fractional anisotropy (FA); functional MRI (fMRI); magnetic resonance imaging (MRI); magnetic resonance spectroscopy (MRS); neuromelanin; pharmacodynamic MRI (phMRI); resting state-fMRI (rs-fMRI); theranostics; voxel-based morphometry (VBM)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Tuite, P. Brain Magnetic Resonance Imaging (MRI) as a Potential Biomarker for Parkinson’s Disease (PD). Brain Sci. 2017, 7, 68.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Brain Sci. EISSN 2076-3425 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top